Search results
Results from the WOW.Com Content Network
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine. [9] Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring. [9]
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.
A recent large-scale study found that severe depression in patients with bipolar disorder responds no better to a combination of antidepressant medications and mood stabilizers than it does to mood stabilizers alone and that antidepressant use does not hasten the emergence of manic symptoms in patients with bipolar disorder.
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [14] and as an appetite stimulant. [15]
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.
Desyrel – an atypical antidepressant used to treat depression and insomnia Desoxyn ( methamphetamine hydrochloride) – used to treat attention deficit hyperactivity disorder and exogenous obesity Dexedrine ( dextroamphetamine sulfate) – used to treat attention deficit hyperactivity disorder and narcolepsy
In general, contraindications to antipsychotic switching are cases in which the risk of switching outweighs the potential benefit. Contraindications to antipsychotic switching include effective treatment of an acute psychotic episode, patients stable on a LAI antipsychotic with a history of poor adherence, and stable patients with a history of self-injurious behavior, violent behavior, or ...
The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden. [ 3 ] In November 1993 Imodium Lingual ( loperamide ) from Janssen Pharmaceutica was released in Germany with Zydis technology.